Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

ROS1 translocations and amplifications in lung cancer brain metastases.

Preusser M, Streubel B, Birner P.

J Neurooncol. 2014 Jun;118(2):425-6. doi: 10.1007/s11060-014-1446-x. Epub 2014 Apr 24. No abstract available.

PMID:
24760415
2.

ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.

Lukas RV, Hasan Y, Nicholas MK, Salgia R.

J Clin Neurosci. 2015 Dec;22(12):1978-9. doi: 10.1016/j.jocn.2015.04.009. Epub 2015 Jul 7.

PMID:
26159887
3.

Miliary brain metastases in a patient with ROS1-rearranged lung adenocarcinoma: a case report.

Dziadziuszko K, Szurowska E, Pienkowska J, Jassem J, Dziadziuszko R.

J Thorac Oncol. 2014 May;9(5):e34-6. doi: 10.1097/JTO.0000000000000091. No abstract available.

4.

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.

Warth A, Muley T, Dienemann H, Goeppert B, Stenzinger A, Schnabel PA, Schirmacher P, Penzel R, Weichert W.

Histopathology. 2014 Aug;65(2):187-94. doi: 10.1111/his.12379. Epub 2014 Apr 3.

PMID:
24456475
5.

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.

Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P.

Lung Cancer. 2013 Jun;80(3):278-83. doi: 10.1016/j.lungcan.2013.01.019. Epub 2013 Feb 27.

PMID:
23453647
6.

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

Gainor JF, Shaw AT.

Oncologist. 2013;18(7):865-75. doi: 10.1634/theoncologist.2013-0095. Epub 2013 Jun 28. Review.

7.

A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.

Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M.

J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.

8.

Coexistence of three variants involving two different fusion partners of ROS1 including a novel variant of ROS1 fusions in lung adenocarcinoma: a case report.

Cai W, Li W, Ren S, Zheng L, Li X, Zhou C.

J Thorac Oncol. 2014 Jun;9(6):e43-6. doi: 10.1097/JTO.0000000000000118. No abstract available.

9.

ROS1-targeted therapy in non-small cell lung cancer.

Sequist LV.

Clin Adv Hematol Oncol. 2012 Dec;10(12):827-8. Review. No abstract available.

PMID:
23271356
10.

[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib].

Svaton M, Pešek M.

Klin Onkol. 2016;29(1):63-5. Czech.

PMID:
26879065
11.

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A.

Lung Cancer. 2014 Feb;83(2):168-73. doi: 10.1016/j.lungcan.2013.11.019. Epub 2013 Dec 1.

PMID:
24380695
12.

ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.

Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H.

Am J Surg Pathol. 2013 Apr;37(4):554-62. doi: 10.1097/PAS.0b013e3182758fe6.

PMID:
23426121
13.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Engelman JA, Shaw AT.

N Engl J Med. 2013 Sep 19;369(12):1173. doi: 10.1056/NEJMc1309091. No abstract available.

14.

ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.

Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ.

Am J Surg Pathol. 2013 Sep;37(9):1441-9. doi: 10.1097/PAS.0b013e3182960fa7.

15.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.

N Engl J Med. 2013 Jun 20;368(25):2395-401. doi: 10.1056/NEJMoa1215530. Epub 2013 Jun 1.

16.

[A new target in non-small cell lung cancer: ROS1 fusion gene].

Cai WJ, Su B.

Zhonghua Zhong Liu Za Zhi. 2013 Jan;35(1):1-4. doi: 10.3760/cma.j.issn.0253-3766.2013.01.001. Review. Chinese. No abstract available.

PMID:
23648291
17.

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Gerlinger M, Norton L, Swanton C.

N Engl J Med. 2013 Sep 19;369(12):1172-3. doi: 10.1056/NEJMc1309091#SA1. No abstract available.

PMID:
24047073
18.

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.

Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, Streubel B, Birner P.

Lung Cancer. 2014 Jan;83(1):83-9. doi: 10.1016/j.lungcan.2013.10.004. Epub 2013 Oct 17.

PMID:
24183471
19.

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design.

Uguen A, Marcorelles P, De Braekeleer M.

J Thorac Oncol. 2015 Aug;10(8):e83-5. doi: 10.1097/JTO.0000000000000605. No abstract available.

20.

ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.

Jänne PA, Meyerson M.

J Clin Oncol. 2012 Mar 10;30(8):878-9. doi: 10.1200/JCO.2011.39.4197. Epub 2012 Jan 3. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk